C3aR, Mouse, mAb 14D4
The monoclonal antibody 14D4 reacts with mouse C3aR, which is a member of the rhodopsin superfamily of 7-transmembrane G protein-coupled receptors, with a molecular weight of approximately 54 kDa.
Read moreThe monoclonal antibody 14D4 reacts with mouse C3aR, which is a member of the rhodopsin superfamily of 7-transmembrane G protein-coupled receptors, with a molecular weight of approximately 54 kDa.
Expression of C3aR has been demonstrated on a wide variety of immune cells, including monocytes, macrophages, dendritic cells, neutrophils, basophils, eosinophils, mast cells, T lymphocytes and B lymphocytes. In addition, C3aR is found on cells of the central nervous system, lungs and kidney. In the course of complement activation C3aR functions as the cell surface receptor for C3a, which is the C-terminal 77 amino acid cleavage product of C3. C3a, possesses both anaphylatoxic and immunoregulatory properties, such as smooth muscle contraction, histamine release from mast cells, and enhanced vascular permeability.
In addition, C3a induces respiratory burst in neutrophils and has chemotactic properties for eosinophils and mast cells. Moreover, C3a causes release of key cytokines from multiple cell types, including IL-1β, TNF-α, IL-6 and IL-8. A role for C3aR has been implicated in several murine disease models. It was shown that C3aR inhibition reduces neurodegeneration in experimental lupus, whereas in a murine model of allergic airway disease, deletion of the C3a receptor protects against the changes in lung physiology seen after allergen challenge. Finally, it was shown that deletion of C3aR is protective in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis.
You may be interested in…
Calculate your ELISA data easily
With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.
Latest Hycult Biotech news
- New Human Complement Pathway AssaysWe are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
- Navigating the pitfalls in complement analysisOur colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis
- NEW Human C3d ELISAWe are happy to introduce our new ELISA (cat.# HK3017) designed to detect human C3d. What sets this assay apart is its utilization of a distinctive neo-epitope capture antibody that selectively targets a specific C3d region of the alpha chain, which is not available in other C3 variants. This way it specifically distinguishes C3d from native C3… Read more: NEW Human C3d ELISA